Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer
Thomas A. Longo(Duke University), Brant A. Inman(Duke Medical Center), Stephen Szabo(GlaxoSmithKline (United States)), Alexander B. Sibley(Duke University), Yuchen Bai(The University of Melbourne), Kouros Owzar(Duke University), Kathleen F. McGinley(Duke University), Joel Greshock(Cancer Research Institute), Wiguins Etienne(Duke University), Yuan Wu(Shanghai Medical College of Fudan University), Jeremy S. Gresham(Cancer Institute (WIA)), Jennifer A. Freedman(Duke Medical Center), Hui Zhou(GlaxoSmithKline (United States)), Christopher Moy(GlaxoSmithKline (United States))
Cited by 21
Related Papers
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
|Journal of Clinical Oncology|2008|655
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|541